1. Jutel M, Kosowska A, Smolinska S. Allergen immunotherapy: past, present, and future. Allergy Asthma Immunol Res. 2016; 8:191–197. PMID:
26922928.
Article
2. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI Guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018; 73:765–798. PMID:
28940458.
3. Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: location does not matter. J Allergy Clin Immunol Pract. 2014; 2:156–160. PMID:
24607042.
Article
4. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008; CD000011. PMID:
18425859.
Article
5. Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy. 2013; 43:22–28. PMID:
23278877.
Article
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353:487–497. PMID:
16079372.
Article
7. Lower T, Henry J, Mandik L, Janosky J, Friday GA Jr. Compliance with allergen immunotherapy. Ann Allergy. 1993; 70:480–482. PMID:
8507043.
8. Calderon MA, Cox L, Casale TB, Mösges R, Pfaar O, Malling HJ, et al. The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey. Allergy Asthma Clin Immunol. 2015; 11:17. PMID:
26015786.
Article
9. Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy. 2010; 65:668–669. PMID:
19845569.
Article
10. Lee JH, Kim SC, Choi H, Jung CG, Ban GY, Shin YS, et al. A Retrospective study of clinical response predictors in subcutaneous allergen immunotherapy with house dust mites for allergic rhinitis. Allergy Asthma Immunol Res. 2018; 10:18–24. PMID:
29178674.
Article
11. Mahesh PA, Vedanthan PK, Amrutha DH, Giridhar BH, Prabhakar AK. Factors associated with non-adherence to specific allergen immunotherapy in management of respiratory allergy. Indian J Chest Dis Allied Sci. 2010; 52:91–95. PMID:
20578401.
12. More DR, Hagan LL. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol. 2002; 88:391–394. PMID:
11991556.
Article
13. Rhodes BJ. Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol. 1999; 82:281–286. PMID:
10094219.
Article
14. Guenechea-Sola M, Hariri SR, Galoosian A, Yusin JS. A retrospective review of veterans' adherence to allergen immunotherapy over 10 years. Ann Allergy Asthma Immunol. 2014; 112:79–81. PMID:
24331403.
15. Senna G, Ridolo E, Calderon M, Lombardi C, Canonica GW, Passalacqua G. Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol. 2009; 9:544–548. PMID:
19823080.
Article
16. Anghel LA, Farcas¸ AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence. 2018; 12:1151–1166. PMID:
30013327.
Article
17. Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res. 2017; 15:434–445. PMID:
29142511.
Article
18. Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013; 132:353–360. PMID:
23651609.
Article
19. Hommers L, Ellert U, Scheidt-Nave C, Langen U. Factors contributing to conductance and outcome of specific immunotherapy: data from the German National Health Interview and Examination Survey 1998. Eur J Public Health. 2007; 17:278–284. PMID:
17060335.
Article
20. Donahue JG, Greineder DK, Connor-Lacke L, Canning CF, Platt R. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol. 1999; 82:339–347. PMID:
10227332.
Article
21. Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017; 5:1519–1531. PMID:
28970084.
Article
22. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007; 120:164–170. PMID:
17543376.
Article